Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Parkinson Disease 2Neuroendocrine Tumors 2Neuroblastoma 2Congenital Hyperinsulinism 2Lewy Body Disease 1Glioma 1Brain Neoplasms 1

Interventions

Radiosurgery 23Radiotherapy 20Temozolomide 17Lomustine 9Bevacizumab 8Surgical Procedures, Operative 7Procarbazine 6Vincristine 5Nivolumab 5Memantine 5Magnetic Resonance Spectroscopy 4Filgrastim 4Etoposide 4Cisplatin 4Carboplatin 4Specimen Handling 3Sodium Chloride 3Radiation 3Methylphenidate 3Mental Status and Dementia Tests 3Granulocyte Colony-Stimulating Factor 3Gefitinib 3Cyclophosphamide 3Corticotropin-Releasing Hormone 3Carmustine 3icotinib 2etoposide phosphate 2efaproxiral 2X-Rays 2Tranexamic Acid 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Brain Neoplasms × fluorodopa F 18 × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡